NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Yes, Nature. Let me explain why it will most probably be Nature.

Below is the chronological list of Robert Prins' work at the UCLA specifically that leads to this article and why it is going to end up in Nature.

2017

It started in 2017 with this work by many from the same UCLA group that led up to the 2023 study lead by Robert Prins, researching WHY checkpoint inhibitors are inefficient without DCVax-L. Prins, Liau and Cloughesy smong others.



2019

From 2019 forward their collective work has been published three times in Nature



Prins and colleagues sought to determine whether neoadjuvant pembrolizumab (Keytruda, Merck), would change the functional immune landscape and improve survival in patients with glioblastoma, which has 3-year survival rate of only 10.1%.

https://www.healio.com/news/hematology-oncology/20190409/neoadjuvant-pembrolizumab-confers-survival-benefit-among-patients-with-glioblastoma

Robert Prins and co. gets their work published in Nature

https://www.nature.com/articles/s41591-018-0337-7




2021

Same team led by Robert Prins: Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma

The work is published in Nature

https://www.nature.com/articles/s41467-021-26940-2



https://www.nature.com/articles/s41467-021-24293-4




And the UCLA article

https://www.uclahealth.org/news/why-certain-brain-tumors-dont-respond-to-immunotherapy

The pre-print (LOOK AT THE TITLE) is supported by NIH (as can be seen below) and as such we can study Robert Prins's grants

LOOK at the team of authors. It is the same stuff they're working on



2007 Prins worked with studying TLR agonists and had grants for 4 years



And then Neoadjuvants (Checkpoint Inhibitors like Keytruda)



Look for NEOADJUVANT AND DCVAX-L




And last. A question for BARD: